Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

Fig. 2

A–F Efficacy of amulirafusp alfa in the Lugano EFS assessed by investigators. A waterfall plot for the best percentage change from baseline measurable lesions. B spider plot for the relative change from baseline measurable lesions. C swimmer plot for the treatment duration and tumor response. D The Kaplan–Meier curve of DoR. E The Kaplan–Meier curve of PFS. F The Kaplan–Meier curve of OS. CR: complete response; CI: confidence interval; DCR: disease control rate; DoR: duration of response; EFS: efficacy set; NE: not evaluable; NR: not reached; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease; SPD: sum of the product of the diameters

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us